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Abstract 
This work describes the synthesis and analysis of radioactive multifunctional 
nanoparticle probes based on CdSe/ZnS semiconductor quantum dots (QDs) for 
potential  in vitro and in vivo anti-cancer theranostics. The synthetic design involved 
the radiosynthesis of luminescent CdSe/ZnS QDs using the SPECT imaging agent 
Cd-109 as the cadmium elemental source. These radioactive nanoparticle materials 
were then rendered water dispersed and bioconjugated to the tumor-targeting ligand 
Rituximab.  
 
 
  
Introduction 
The term “Theranostics” is commonly used to define the development of specific 
individualised therapies for a range of medical conditions, such as tumour diagnosis 
and therapy. Theranostics serves to combine diagnosis and therapy into a single 
tool[1]. The concept of cancer theranostics arose from the observation that cancer 
tumours are naturally heterogeneous in nature, that is, no two tumours, even in the 
same patient, will respond the same way to the same general treatment[2]. Therefore, 
a system needed to be developed where diagnosis and treatment could be performed 
on an individual tumour basis. 
The goal of targeted theranostics is to create platforms that are specifically designed 
to provide more effective tumour imaging while reducing the degree of toxicity 
administered to healthy tissue during tumour treatment[2,3]. Nanoparticle research 
offers the possibility of a platform incorporating a combined real-time imaging  and  
targeted therapy in one, with multiple novel capabilities. Nanoparticles have been 
shown to have the potential  to be a more effective and  selective delivery platform 
for therapeutics into tumour sites than conventional drug delivery systems[4-11].  
Nanoparticles are nanometer scale particles made of either inorganic metal 
compounds[12] or polymer materials[13]. They are molecules composed of atoms 
from group II-VI (CdSe, CdTe, CdS) or III-V (InP, InAs) elements in the periodic 
table[13,14]. Their composition and small size (a few hundred to a few thousand 
atoms) give these particles powerful fluorescent and optical properties that can be 
readily customized by changing the size or composition of the nanoparticle[12]. 
Nanoparticles absorb light of a lower wavelength, then quickly re-emit the light but in 
a higher specific narrow wavelength[4-11].  
  
Nanoparticles have many unique optical properties. The most striking property is that 
the colour of the absorption and emission, created from the nanoparticle, can be tuned 
to any chosen wavelength by simply changing their size[13-15].  
Previously, nanoparticles have been developed for cancer tumour imaging, based on 
their ability to act as tagged fluorescent markers[10-12]. These nanoparticles can be 
selectively functionalised in order to  bind to a range of biomolecules (proteins, 
peptides, nucleic acids, antibodies, etc.)[16,17]. Once functionalised the nanoparticles 
can be localised in tumour cells through a number of mechanisms including for 
example, receptor binding, enzyme activation, and expression of a specific gene 
product[18-20]. The nanoparticles give distinct intense localised fluorescence, 
depending on the wavelength of the light emitted, allowing the optical imaging of 
several pathways associated with the tumour and its environment.  
The development of nanoparticles have become promising tools as fluorescence 
markers in various diagnostic applications and they have also been suggested as drug 
delivery vehicles with the purpose of achieving a high therapeutic index[5]. However, 
in all the in vivo applications described so far, high concentrations (10-100mg/ml) of 
nanoparticles have been used and this has raised major issues over toxicity, 
particularly of cadmium based nanoparticles.  The data generated here  shows the 
development of tracer quantities of radioactive nanoparticles that are synthesised 
using radioisotopes, such as the single photon emission computer tomographic 
(SPECT) imaging agents, Cadmium-109 (t½ = 462.6d, 88KeV γ-ray)  or Selenium-70 
(t½ = 41.1m, β+).  Such tracer radioactive nanoparticles will overcome the potential 
toxicity of the administration of cadmium based nanoparticles whilst maintaining the 
therapeutic and imaging functionalities of these particles.  
  
  
The development of nanoparticles at both carrier added (containing both stable and 
radioactive isotope) and tracer levels (radioisotope only) from radioisotopes of the 
same elements as those used in the synthesis of conventional nanoparticle quantum 
dots[13-15]. Synthesis at the tracer level will allow the exploration of these inorganic 
metals as combined imaging and therapeutic agents, both in their radioactive form, 
for instance γ-emitters localised in tumour cells, and in their chemotherapeutic form, 
for example,  toxic decay products created by the nanoparticle breakdown or by the 
nanoparticle release of toxic daughter isotopes.  
 
Experimental 
Materials 
All reagents were purchased from Sigma-Aldrich U.K. unless otherwise indicated. 
Cadmium-109 was purchased from Amersham Biosciences, U.K. UV analysis was 
carried out on a Cary 300 Bio UV-vis spectrophotometer (Agilent, U.S.A.), 
Fluorescence analysis was carried out using a Nanodrop ND-3300 fluorospectrometer 
(Thermofisher, U.K.). SEM was carried out on a Topcon DS 130F field emission 
scanning electron microscope (Topcon Corporation, Tokyo, Japan). Gamma ray 
spectroscopy was carried out on a Gammavision-32 gamma ray spectrometer 
(ORTEK, U.K.). 
 
Synthesis of Carrier added [109Cd]CdSe  
Highly fluorescent [109Cd]CdSe nanoparticles were synthesised by  procedures 
modified from those reported previously[13]. For a typical reaction, the mixture of 
25.0mg, (0.2 mM) of cadmium oxide (CdO), 3.0 mL of 1-octadecene (ODE) 
containing 37 MBq, 1 mCi of cadmium-109 cadmium chloride ([109Cd]CdCl 
  
(10µM)),  and 227.0mg, (0.8 mmol) of stearic acid in a 25 mL three-neck flask was 
heated to 200 oC for 10 min to obtain a colourless clear solution.  Following cooling 
to room temperature, octadecylamine (ODA, 1.5 g) and 0.5 g of Tri-n-octylphosphine 
oxide (TOPO) were added into the flask. Under argon flow, this system was reheated 
to 280oC. At this temperature, a selenium solution made by dissolving 68mg, (2.0 
mM) of Se in 2.0 mL of tri-butyl phosphine (TBP) and 1.5 mL of ODE was quickly 
injected. The crystaline growth temperature was then reduced to 250 oC. This reaction 
generated [109Cd]CdSe nanoparticles of about 3.5-10.0 nm in size with the first 
absorption peak around 570 nm. The reaction mixture was allowed to cool to room 
temperature, and an extraction procedure involving the addition of methanol/heptane 
1:1  was used to purify the nanoparticles from side products and unreacted precursors. 
The purified cadmium-109 cadmium selenide ([109Cd]CdSe) solution in heptane was 
used as a stock solution. 
 
Synthesis of tracer level [109Cd]CdSe nanoparticles 
The above procedure was repeated except that stable CdO was omitted from the 
reaction matrix and the only cadmium source was supplied by the 37 MBq, 1 mCi of 
[109Cd]CdCl (10µM) added to the reaction melt.  
 
Coating with Zinc sulphide (ZnS) 
TOPO (5g) was added to a three necked flask under argon and heated  to 200oC for 1 
hour. The solution was then cooled to 60oC and 0.5 mL of Tri-n-octylphosphine 
(TOP) and the [109Cd]CdSe in heptane added. This mixture was then heated under 
argon to 220 ºC.  A capping solution of 0.1 mM dimethylzinc and 0.1 mM 
hexamethlydisilathiane in 5 ml TOP was slowly added to the [109Cd]CdSe 
  
TOPO/TOP solution over a time course of 10 min at 220 ºC. The reaction was heated 
at 220 ºC  for 30 min. The temperature was then reduced to 90oC for 2 hours. The 
[109Cd]CdSe/ZnS nanoparticles formed had emission wavelength approximately 30 
nm higher than the original [109Cd]CdSe nanoparticles with excellent chemical and 
photo stability. The reaction mixture was then cooled to room temperature, and the 
dots were extracted with solvent methanol/heptane mixture (v/v 1:1). 
 
Water dispersion of [109Cd]CdSe 
[109Cd]CdSe[21] nanoparticles (100 µl TOPO coated in toluene) in a polypropylene 
vial were washed and centrifugally precipitated with 3 x 1ml of methanol at 9000g for 
15 min. The final pellet was re-suspended in 50 µl of chloroform, to which 25 µl of 
mercaptoacetic acid, followed by 25 µl of tetramethylammonium hydroxide (25% 
solution in methanol) were added. After sealing the vial, the mixture was sonicated 
for 1 minute and allowed to stand overnight. The mixture was then maintained at 
60oC in a water bath for one hour. At the end of this time the nanoparticles were 
centrifugally precipitated for ten minutes at 9000g. The supernatant was carefully 
removed, and then the pellet was washed with 2 x 1ml of methanol at 9000g for 15 
minutes. The final pellet was suspended in 1 ml of 10 mM sodium bicarbonate 
solution and stored in the dark. 
 
Direct reaction of [125I]NaI with Rituximab 
Iodine-125 (Amersham Pharmacia Biotech) was used for the development of the 
radiolabelling method for Rituximab and for animal biodistribution studies. Iodogen 
(1,3,4,6-tetrachloro-3α,6α-diphenylglycouril, Sigma) was dissolved in 
dichloromethane (0.4 mg/ml) and dispensed into microfuge tubes (20 μl in 0.5 ml 
  
tubes; 80 μl in 1.5 ml tubes). A reaction mixture consisting of rituximab (50–100 μg) 
and iodine-125 (10–150 MBq) in binding buffer was prepared and dispensed into the 
coated microfuge tubes and these were left at room temperature for 20 min. The 
reaction was terminated by transferral of the solutions directly to either a fresh tube 
(for ITLC analysis using 10% TCA as the mobile phase to determine whether the 
reaction was complete) or to a PD-10 column that had previously been blocked with 
BSA and washed with either binding buffer or PBS. The radiolabelled protein was 
eluted with either binding buffer or PBS and 0.5 ml fractions were collected. 
 
Bioconjugation to [125I]Rituximab to carboxylated nanoparticles [21]. 
[109Cd]CdSe/ZnS nanoparticles (200µL) were added to a solution of 1-ethyl-3-(3-
dimethylaminopropyl)carboiimide (EDC, 0.4 mg 2mM) and N-hydroylsulfo-
succinimide (N-sulfo-NHS, 1.1mg, 5mM) in 0.1 M MES, 0.5M NaCl,  pH 6.0 buffer 
and incubated at room temperature for 20 min. The reaction was then quenched by 
the addition of 2-mercaptoethanol (1.4µl, 20mM) and incubated at room temperature 
for 10 min. The activated [109Cd]CdSe/ZnS  were then adjusted to pH 7.0.  The 
[125I]Rituximab was then bio-conjugated to the [109Cd]CdSe/ZnS. The protein, at a 
2:1 to 5:1 molar ratio of biomolecule to dot, was dissolved in 1 ml PBS (1x, pH 7.5). 
The combined [109Cd]CdSe/ZnS and [125I]Rituximab solution was adjusted to pH 7.5 
with NaOH and incubated at room temperature for 2 hours with continuous gentle 
mixing. Unconjugated [125I]Rituximab was then removed by washing using a 
Nanosep 300k spin filter (Pall Corp. USA). In terms of final concentration, 1 mCi of 
Cd-109 is 3.5 nmol in 1 mL of solution. This would be equivalent would be 3.5 
µM.  If the final particle concentration is 30 nM, this would give approximately 100 
  
Cd-109 atoms in each nanoparticle.  Gamma ray spectroscopy was then carried out on 
the [125I]R1tuximab bioconjugated [109Cd]CdSe/ZnS. 
 
Results 
This study aimed to develop a paradigm for tumour targeting and imaging using 
radiolabelled nanoparticles. The first step developed and optimized  methods for the 
synthesis of [109Cd]CdSe/ZnS water soluble quantum dots (Scheme 1).  
 
Scheme 1. Synthesis of core/shell radio- nanoparticles.   
   
Based upon the methods developed by Peng et.al.[14] and Nie. et.al.[15] the synthesis 
of CdSe/ZnS core/shell nanoparticles have been modified to allow the incorporation 
of the single photon emission computer tomographic (SPECT) isotope cadmium-109 
to form  [109Cd]CdSe/ZnS core-shell quantum dots. The progress of the formation of 
the CdSe nanoparticles involving the introduction of [109Cd]cadmium  into the 
reaction melt was monitored by recording the UV spectra (Fig. 1a) and fluorescence 
spectra (Fig. 1b)  of aliqouts taken from the reaction vessel over the period of one 
minute. 
 
 
 
 
 
  
 
Figure 1a. UV spectra of [109Cd]CdSe nanoparticles. All of the reactions were 
performed under the same conditions, except the reaction time was increased by 10 
seconds in each case. The Cd:Se molar ratio was 1:1. Figure 1b. Fluorescence of 
Carrier added CdSe nanoparticles. 
 
These results obtained are consistent with the published literature[14,15] for stable 
CdSe nanoparticle production. This reaction was then repeated using tracer level 
cadmium only ([109Cd]CdCl3, 37MBq, 1mCi). The cadmium reaction concentrations 
equate to nmol levels of cadmium present in the reaction melt. All other parameters 
remained the same as in the carrier added reaction shown in Figure 1a and 1b. The 
reaction was monitored by recording the UV spectra (Fig. 2a) and fluorescence 
spectra (Fig. 2b) of aliqouts taken from the reaction vessel over the period of one 
minute. However, no nanoparticle formation was observed over this time course. This 
is due to the greatly reduced concentration of cadmium-109 in the tracer only reaction 
reducing the reaction kinetics and slowing the formation of [109Cd]CdSe. The reaction 
 
 
  
melt was allowed to continue heating at 280oC for 1- 2 hours. Over this period of time 
the reaction melt slowly changed in colour from clear to red. Figure 2 shows UV and 
fluorescence analysis of the tracer level batch after 2 hours. 
 
Figure 2. UV (2A) and fluorescence (2B) spectral analysis of the synthesis of tracer 
level [109Cd]CdSe. 
The first stage of synthesis using, either carrier added or tracer level,  generated 
mono-dispersed [109Cd]CdSe nanoparticles ranging in size from 2-10nm, as 
demonstrated in the scanning electron micrograph (SEM) shown in Figure 3. These 
nanoparticles were synthesised using a high-temperature colloidal growth method 
followed by size selective precipitation with methanol[15,16].  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
                  
 
Figure 3. Scanning electron micrograph of the [109Cd]CdSe quantum dots produced 
by tracer level synthesis. 
 
By using the extinction coefficients for CdSe published in the literature[21] (ε=3.7 
105 L/mol cm  for CdSe and  =3.5 105 L/mol cm  for CdSe/ZnS at a path length 1 cm), 
for the first excitonic absorption peak (Fig. 1a and Fig. 2a) of the nanoparticles along 
with particle size analysis, which indicated a particle size of 5-10nm (Fig. 3), it has 
been possible to calculate the concentration of [109Cd]CdSe particles produced at both 
carrier added and tracer level. From the analysis, it was possible to deduce that the 
concentration of carrier added [109Cd]CdSe was approximately 3-4 µmolL-1, whereas 
the concentration of tracer [109Cd]CdSe was estimated to be approximately 
0.03µmolL-1. Currently, the maximum permissible exposure dose for cadmium is 2.5 
µgkg-1 of body weight[22]. 
 
These show that the concentration of nanoparticles at tracer level is approximately 
two orders of magnitude lower than the concentration of nanoparticles produced at 
carrier added level. However, the fluorescence spectra (Fig. 1b and Fig. 2b) of the 
 
  
nanoparticles shows that even though smaller  numbers of nanoparticles are produced 
over longer periods of time, they still retaine there ability to fluoresce.  
 
                                                                                                        B 
 
 
Figure 4. UV-vis (a)  and fluorescence (b) analysis of  [109Cd]CdSe and  
[109Cd]CdSe/ZnS  
A 
  
Figure 4 also shows the comparison of  absorption spectra (Fig. 4a) and fluorescence 
spectra (Fig. 4b) of   [109Cd]CdSe core and [109Cd]CdSe/ZnS core-shell nanoparticle.  
It can be seen from the absorption spectra that when the nanoparticles are shelled with 
ZnS that there is an inherant  redshift of 15nm[23]. We observed a shift in the 
absorption and fluorescence spectra (Fig. 4b) to the red (lower energies) after 
overcoating due to partial leakage of the exciton into the ZnS matrix[23]. 
 
Figure 5. Gamm-ray spectroscopy of [109Cd]CdSe/ZnS nanoparticles 
Gamma ray spectroscopy of the nanoparticles also indicates better than 90% uptake 
of the radioactive isotope  in to the crystaline structure of the  nanocrystal at tracer 
level synthesis (Figure 5). 
 
Water dispersion of the [109Cd]CdSe/ZnS was carried out using  mercaptoacetic acid, 
and  tetramethylammonium hydroxide. Observation of the fluorescence after water 
dispersion clearly indicated a drop of 80-90% fluorescence emission from the dots 
  
(Figure 6). This drop in fluorescence may be due to  the decreased pH of the system 
quenching the nanoparticles [24]. However, gamma-ray spectroscopy indicated little 
loss of activity from the organic  [109Cd]CdSe/ZnS stage to the water dispersion stage.  
 
Figure 6. Loss in fluorescence during dispersion between organic and aqueous phase 
Once the nanoparticles were rendered water dispersed it was necessary to 
bioconjugate the nanoparticles to a potential cancer marker which would demonstrate 
a possible future therapeutic application. The protein that was selected was the anti-
CD-20 antibody rituximab[25]. This was done in order to demonstrate the potential 
biological uptake onto the surface of radio-nanoparticles. The reason for the selection 
of the Anti-CD-20 antibody rituximab, is that antibodies of this type have been 
sucessfully directed against cell surface targets and have already had a significant 
impact in oncology, cardiology, and immunology in the therapeutic realm[26]. The 
success of drugs such as rituximab attests to the ability of antibodies to localize and 
  
engage or block critical biologic targets in patients. Also, rituximab has shown itself 
to be very aminable to rdiolabelling for PET and SPECT scanning in the past. 
 In order to measure the percentage efficiency of protein binding to the 
[109Cd]CdSe/ZnS, the rituximab was  radiolabelled with the SPECT imaging agent I-
125 which has distinct γ-rays at 35.5KeV[27]. The radioiodination process was 
carried out as described previously[27]. Gamma ray spectroscopy indicated 
[125I]Rituximab was bound to the [109Cd]CdSe/ZnS at the end of the bioconjugation 
process (Figure 7).  
 
Figure 7 – Gamma ray spectrum of [109Cd]CdSe/ZnS-[125I]Rituximab 
Overall γ-ray spectroscopy indicated that approximately 40% of the starting 
cadmium-109 was lost between the start of the synthesis of [109Cd]CdSe and the final 
bioconjugation wash (Figure 8). 
  
 
 
Figure 8. Loss profile of Cd-109 activity at each step in the synthesis. 
 
Conclusion 
This study demonstrates the synthesise of nanoparticles containing carrier free levels  
of a radioisotope used to form  the nanoparticles, and subsequent bioconjugation of 
these nanoparticles to proteins of biological importance. In this case cadmium-109 
was used. The nanoparticles  produced were at tracer level, therefore, allowing the 
cadmium-109  SPECT imaging agent to be incorporated into a nanoparticle, which 
could allow for injection of the imaging agent into a subject at dramatically reduced 
levels of heavy metal toxicity. Currently, injection of a SPECT or positron emission 
tomographic (PET) radio imaging agent results in high signal to noise ratio, due to 
  
high metabolism of the radiopharmaceutical. This metabolism may be reduced by 
locking the radioisotope in a stable crystaline structure, and coating the structure in a 
large number of molecules of the drug or targeting agent of interest. The 
incorporation of the tracer leveel radioisotope may also allow for a possible 
radiotheraputic application, if enough radioactivity could be internally localised into 
the tumour. 
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Highlights 
 This work describes the synthesis and analysis of radioactive multifunctional 
nanoparticle probes based on CdSe/ZnS semiconductor quantum dots (QDs) 
for potential  in vitro and in vivo anti-cancer theranostics.  
 The synthetic design involved the radiosynthesis of luminescent CdSe/ZnS 
QDs using the SPECT imaging agent Cd-109 as the cadmium elemental 
source.  
 These radioactive nanoparticle materials were then rendered water soluble and 
bioconjugated to the tumor-targeting ligand Retuximab.  
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